Search hospitals

>

North Carolina

>

Chapel Hill

UNC Lineberger Comprehensive Cancer Center

Claim this profile

Chapel Hill, North Carolina 27514

Global Leader in Breast Cancer

Global Leader in Cancer

Conducts research for Leukemia

Conducts research for Lung Cancer

Conducts research for Lymphoma

887 reported clinical trials

71 medical researchers

Photo of UNC Lineberger Comprehensive Cancer Center in Chapel HillPhoto of UNC Lineberger Comprehensive Cancer Center in Chapel HillPhoto of UNC Lineberger Comprehensive Cancer Center in Chapel Hill

Summary

UNC Lineberger Comprehensive Cancer Center is a medical facility located in Chapel Hill, North Carolina. This center is recognized for care of Breast Cancer, Cancer, Leukemia, Lung Cancer, Lymphoma and other specialties. UNC Lineberger Comprehensive Cancer Center is involved with conducting 887 clinical trials across 715 conditions. There are 71 research doctors associated with this hospital, such as Emily Greengard, Stuart H. Gold, David E. Kram, and Jared Weiss, MD.

Area of expertise

1

Breast Cancer

Global Leader

UNC Lineberger Comprehensive Cancer Center has run 127 trials for Breast Cancer. Some of their research focus areas include:

ER positive
HER2 negative
Stage IV
2

Cancer

Global Leader

UNC Lineberger Comprehensive Cancer Center has run 105 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage I

Top PIs

Clinical Trials running at UNC Lineberger Comprehensive Cancer Center

Breast Cancer

Bladder Cancer

Skin Cancer

Cancer

Breast cancer

Ovarian Cancer

Bladder Carcinoma

Pancreatic Cancer

Kidney Cancer

Testicular cancer

Image of trial facility.

Low Dose Tamoxifen

for Breast Cancer

This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.

Recruiting

2 awards

Phase 3

8 criteria

Image of trial facility.

Omitting Radiation Therapy

for Breast Cancer

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.

Recruiting

2 awards

Phase 3

19 criteria

Image of trial facility.

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.

Recruiting

2 awards

Phase 3

47 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at UNC Lineberger Comprehensive Cancer Center?

Where is UNC Lineberger Comprehensive Cancer Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does UNC Lineberger Comprehensive Cancer Center accept?

What awards or recognition has UNC Lineberger Comprehensive Cancer Center received?